In your trust how many patients with Multiple Sclerosis have been treated with
MS disease modifying drugs in the past 6 months, latest 6 months that you can provide.
Please provide the number of patients by treatment for the following disease modifying drugs.
Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Copaxone (glatiramer acetate)
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Lemtrada (alemtuzumab)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Ampyra (Fampyra)
Peginterferon beta-1a (Plegridy)
Daclizumab (Zinbryta)
Ocrevus (Ocrelizumab)
Others
